NorthWest Biotherapeutics Inc (NWBO)

[MolBiol]

The problem with this theory is that the primary endpoint is the surrogate. This is not a trial with a primary endpoint that is based on clinical efficacy with some additional surrogate endpoints. In a trial such as that you could argue that a surrogate endpoint is predictive of clinical benefit AND if that surrogate data were statistically significant then maybe it could be used for AA while waiting for the clinical benefit (efficacy). That is not what we have here with -L. Additionally, the p-value required to make the data significant at 66 events is not p<0.05; it's much smaller. You don't get a pass on demonstrating that the data are reliable.